gBRCA突变转移性胰腺癌维持奥拉帕利治疗的健康相关生活质量分析
POLO试验预设HRQoL分析显示,gBRCA突变转移性胰腺癌患者维持奥拉帕利治疗期间整体健康状况保持稳定,与安慰剂组无临床意义差异,支持其疗效获益。
要点
- 奥拉帕利组与安慰剂组整体健康状况评分变化均小于10分,组间无显著差异。
- 躯体功能评分组间差异虽达统计学显著,但未达临床意义阈值。
- 至持续临床意义恶化时间两组无差异,HRQoL在维持治疗中得以保持。
核心结论
- 维持奥拉帕利治疗期间HRQoL得以保持,与安慰剂相比无临床意义差异,支持其疗效获益。
研究设计与样本
- POLO为随机双盲III期试验,纳入154例gBRCA突变转移性胰腺癌患者,HRQoL分析纳入奥拉帕利组89例和安慰剂组58例。
- 使用EORTC QLQ-C30量表在基线、每4周至疾病进展、停药时及末次给药后30天评估HRQoL。
主要发现
- 整体健康状况评分基线调整后平均变化两组均小于10分,组间差异-2.47(95%CI -7.27, 2.33;P=0.31)。
- 躯体功能评分组间差异-4.45分(95%CI -8.75, -0.16;P=0.04)。
- 整体健康状况至持续临床意义恶化时间无差异(P=0.25;HR 0.72;95%CI 0.41, 1.27)。
- 躯体功能至持续临床意义恶化时间无差异(P=0.32;HR 1.38;95%CI 0.73, 2.63)。
关键数值与推荐
- 评分范围0至100,组间差异或变化≥10分视为临床意义。
- 整体健康状况和躯体功能至持续临床意义恶化时间采用log-rank检验分析。
临床怎么用
- 对于gBRCA突变转移性胰腺癌患者,维持奥拉帕利治疗不损害HRQoL,可支持临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase inhibitor, than placebo in patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy. The prespecified HRQoL evaluation is reported here. PATIENTS AND METHODS: Patients were randomized to receive maintenance olaparib (300 mg b.i.d.; tablets) or placebo. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module at baseline, every 4 weeks until disease progression, at discontinuation, and 30 days after last dose. Scores ranged from 0 to 100; a ≥10-point change or difference between arms was considered clinically meaningful. Adjusted mean change from baseline was analysed using a mixed model for repeated measures. Time to sustained clinically meaningful deterioration (TSCMD) was analysed using a log-rank test. RESULTS: Of 154 randomized patients, 89 of 92 olaparib-arm and 58 of 62 placebo-arm patients were included in HRQoL analyses. The adjusted mean change in Global Health Status (GHS) score from baseline was <10 points in both arms and there was no significant between-group difference [-2.47; 95% confidence interval (CI) -7.27, 2.33; P = 0.31]. Analysis of physical functioning scores showed a significant between-group difference (-4.45 points; 95% CI -8.75, -0.16; P = 0.04). There was no difference in TSCMD for olaparib versus placebo for GHS [P = 0.25; hazard ratio (HR) 0.72; 95% CI 0.41, 1.27] or physical functioning (P = 0.32; HR 1.38; 95% CI 0.73, 2.63). CONCLUSIONS: HRQoL was preserved with maintenance olaparib treatment with no clinically meaningful difference compared with placebo. These results support the observed efficacy benefit of maintenance olaparib in patients with a gBRCAm and metastatic pancreatic cancer. CLINCALTRIALS.GOV NUMBER: NCT02184195.
引用
- Hammel P, Kindler HL, Reni M, et al. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019. PMID: 31562758. doi:10.1093/annonc/mdz406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。